Results 41 to 50 of about 1,442,988 (353)
In Vivo Secretion of Bispecific Antibodies Recruiting Lymphocytic Effector Cells
Antibodies, 2013 Engineered Fc-lacking bispecific antibodies have shown an exceptionally high potency for recruiting lymphocyte effector cells and enhancing antitumor activity, which is under evaluation in several clinical trials.
Luis Alvarez-Vallina +3 more
doaj +1 more source
Emerging Antibodies in Cancer Therapy
Advanced NanoBiomed Research, 2023 Since the first monoclonal antibody, Orthoclone OKT3, was approved in 1986 for the treatment of acute allograft rejection in renal transplant recipients, the number of antibody‐based therapies has increased remarkably, with more than 130 monoclonal ...
Yaping Sun, Jian Xu
doaj +1 more source
Recent advances and challenges of bispecific antibodies in solid tumors
Experimental Hematology & Oncology, 2021 Cancer immunotherapy has made remarkable progress in the past decade. Bispecific antibodies (BsAbs) have acquired much attention as the next generation strategy of antibody-target cancer immunotherapy, which overwhelmingly focus on T cell recruitment and
Yuze Wu +4 more
semanticscholar +1 more source
Bispecific antibodies in cancer immunotherapy [PDF]
Human Vaccines & Immunotherapeutics, 2016 Cancer immunotherapy has recently generated much excitement after the continuing success of the immunomodulating anti-CTLA-4 and anti-PD-1 antibodies against various types of cancers. Aside from these immunomodulating antibodies, bispecific antibodies, chimeric antigen receptor T cells, and other technologies are being actively studied.
Zhong Wang, Qing Li, Siqi Chen, Jing Li
openaire +2 more sources
Cancer Medicine, Volume 11, Issue 24, Page 5097-5112, December 2022., 2022 our findings robustly demonstrate that our constructed prlncRNA signature could serve as an efficient indicator of prognosis, immunotherapy response, and chemosensitivity for HNSCC patients. Abstract Background Pyroptosis plays an essential function in carcinogenesis and the antitumor immune response.
Chongchang Zhou +6 more
wiley +1 more source
Bispecific Antibodies in Multiple Myeloma: Present and Future.
Blood Cancer Discovery, 2021 Despite many recent advances in therapy, there is still no plateau in overall survival curves in multiple myeloma. Bispecific antibodies are a novel immunotherapeutic approach designed to bind antigens on malignant plasma cells and cytotoxic immune ...
G. Lancman +9 more
semanticscholar +1 more source
How to improve the quality of comparisons using external control cohorts in single-arm clinical trials? [PDF]
arXiv, 2022 PURPOSE Providing rapid answers and early acces to patients to innovative treatments without randomized clinical trial (RCT) is growing, with benefit estimated from single-arm trials. This has become common in oncology, impacting the approval pathway of health technology assessment agencies.
arxiv
Antibody Watch: Text Mining Antibody Specificity from the Literature [PDF]
PLOS Computational Biology, 2021, 2020 Antibodies are widely used reagents to test for expression of proteins and other antigens. However, they might not always reliably produce results when they do not specifically bind to the target proteins that their providers designed them for, leading to unreliable research results.
arxiv +1 more source
Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size
Fluids and Barriers of the CNS, 2021 Background Transferrin receptor (TfR1) mediated enhanced brain delivery of antibodies have been studied extensively in preclinical settings. However, the brain pharmacokinetics, i.e.
Rebecca Faresjö +5 more
semanticscholar +1 more source
Cancer, Volume 129, Issue 2, Page 255-263, 15 January 2023., 2023 Abstract Background Autologous anti‐CD19 chimeric antigen receptor (CAR) T‐cell therapy is an effective treatment for approximately 40% of relapsed/refractory large B cell lymphomas (LBCL), and early identification of patients at risk for relapse or progression after CAR T‐cell therapy represents a clinical need.
Anna Guidetti +14 more
wiley +1 more source